Q2 saw broad-based revenue and earnings growth, with adjusted EPS up over 40% year-over-year and all segments outperforming. Full-year 2026 guidance was raised for EPS and cash flow, and technology investments are driving operational gains. 340B headwinds and Caremark membership declines are expected in 2027, but strong specialty pharmacy and digital initiatives support long-term growth.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.